Viney Jain News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Viney jain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Viney Jain Today - Breaking & Trending Today
DRDO s drug was effective on brain cancer patients, can t say about Covid-19 DRDO’s drug was first used in a human clinical study on brain tumour patients by Dr A K Banerji at AIIMS, Delhi, along with Dr Viney Jain, former director of INMAS LAB. Share Via Email | A+A A- Dr AK Banerji who served at AIIMS neurosurgery department for 30 years, said that the drug was reasonably effective on cancer. Express News Service NEW DELHI: Oral anti-viral drug 2-deoxy-D-glucose (2-DG), developed by the DRDO and being touted as a potential game-changer in the battle against Covid-19, was first used in a human clinical study on brain tumour patients by Dr A K Banerji at AIIMS, Delhi, along with Dr Viney Jain, former director of INMAS LAB (DRDO). ....
Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August Data Suggests Phase-3 Trials For Covid Drug 2-DG May Continue Till August The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally. New Delhi: With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. ....
With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author. ....
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. ....